These 2 Breast Cancer Treatment Makers Will Rise as Another Falls Motley Fool In addition, Roche and Halozyme's MabThera SC -- a subcutaneous version of Roche's cancer and arthritis drug rituximab -- is under regulatory review in the EU. Another failure at Eli Lilly As Roche and Halozyme shareholders celebrated, shares of Eli ... |
